Reihaneh Haghniaza,b,c,1, Han-Jun Kimb,c,1, Hossein Montazeriana,b,c, Avijit Baidyab, Maryam Tavafoghia,b, Yi Chena,b,c, Yangzhi Zhuc, Solmaz Karamikamkarc, Amir Sheikhia,b,d,e, Ali Khademhosseinia,b,c
aDepartment of Bioengineering, University of California, Los Angeles, 410 Westwood Plaza, Los Angeles, CA, 90095, United States
bCalifornia NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA, 90095, United States
cTerasaki Institute for Biomedical Innovation, 11570 W Olympic Boulevard, Los Angeles, CA, 90024, United States
dDepartment of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, United States
eDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, PA, 16802, United States
Corresponding authors: Amir Sheikhi, Ali Khademhosseini
1These authors contributed equally to this work.
Blood loss by hemorrhaging wounds accounts for over one-third of ∼5 million trauma fatalities worldwide every year. If not controlled in a timely manner, exsanguination can take lives within a few minutes. Developing new biomaterials that are easy to use by non-expert patients and promote rapid blood coagulation is an unmet medical need. Here, biocompatible, and biodegradable microneedle arrays (MNAs) based on gelatin methacryloyl (GelMA) biomaterial hybridized with silicate nanoplatelets (SNs) are developed for hemorrhage control. The SNs render the MNAs hemostatic, while the needle-shaped structure increases the contact area with blood, synergistically accelerating the clotting time from 11.5 min to 1.3 min in vitro. The engineered MNAs reduce bleeding by ∼92% compared with the untreated injury group in a rat liver bleeding model. SN-containing MNAs outperform the hemostatic effect of needle-free patches and a commercial hemostat in vivo via combining micro- and nanoengineered features. Furthermore, the tissue adhesive properties and mechanical interlocking support the suitability of MNAs for wound closure applications. These hemostatic MNAs may enable rapid hemorrhage control, particularly for patients in developing countries or remote areas with limited or no immediate access to hospitals.